BOSTON, May 13, 2024
/PRNewswire/ -- Aktis Oncology, a biotechnology company discovering
and developing novel targeted alpha radiopharmaceuticals to treat a
broad range of solid tumors, today announces an oral presentation
at the Oligonucleotide & Peptide Therapeutics (TIDES
USA) Conference 2024, being held
May 14-17, 2024, in Boston, Mass. and virtually. Presentation
details can be found below and additional general conference
information can be found on the TIDES website here.
Presentation Details
|
Presenter:
|
Paul Feldman, Ph.D.,
Chief Scientific Officer, Aktis Oncology
|
|
Title:
|
"Pioneering Aktis
Oncology's Miniprotein Radioconjugates"
|
|
Session:
|
Peptide Discovery
to CMC
|
|
Location:
|
Hynes Convention
Center, Boston, Mass.
|
|
Date:
|
Friday, May 17,
2024
|
|
Time:
|
11:15 a.m.
ET
|
About Aktis Oncology
Aktis Oncology is a biotechnology company pioneering the
discovery and development of a new class of targeted alpha
radiopharmaceuticals to treat a broad range of solid tumor cancers.
Founded and incubated by MPM Capital, the company has developed
proprietary platforms to generate tumor targeting agents with ideal
properties for alpha radiotherapy. Designed for high tumor
penetration and long residence time, Aktis Oncology's molecules
will quickly clear other areas of the body, thereby maximizing
tumor elimination while minimizing side effects of treatment. This
approach would enable clinicians to visualize and verify target
engagement prior to exposure to therapeutic radioisotopes. To learn
more about Aktis Oncology, visit www.aktisoncology.com.
MEDIA CONTACT
Terri Clevenger
ICR Westwicke
(203) 682-8297
Terri.Clevenger@westwicke.com
INVESTOR CONTACT
Peter Vozzo
ICR Westwicke
(443) 213-0505
Peter.Vozzo@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aktis-oncology-announces-presentation-at-the-oligonucleotide--peptide-therapeutics-tides-usa-conference-2024-302143244.html
SOURCE Aktis Oncology